RESUMO
A single pill daily fixed dose combination of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) provides a potent and convenient treatment option for HIV/AIDS. The components have been shown to be well tolerated and are effective in randomized controlled trials. A literature search revealed no case of hepatic failure reported with this drug combination. We here in describe the 1st case of acute hepatic failure developing after 3 months of treatment with EFV/FTC/TDF in a 41 year old African American male without pre-existing liver disease or risk factors.
Assuntos
Adenina/análogos & derivados , Desoxicitidina/análogos & derivados , Falência Hepática/induzido quimicamente , Organofosfonatos/efeitos adversos , Oxazinas/efeitos adversos , Inibidores da Transcriptase Reversa/efeitos adversos , Adenina/efeitos adversos , Adulto , Desoxicitidina/efeitos adversos , Combinação de Medicamentos , Combinação Efavirenz, Emtricitabina, Fumarato de Tenofovir Desoproxila , Infecções por HIV/tratamento farmacológico , Humanos , MasculinoRESUMO
We report a case of rhabdomyolysis associated with the use of trimethoprim-sulfamethoxazole (TMP-SMX) in a newly diagnosed AIDS patient with presumed Pneumocystis jiroveci (formerly named Pneumocystis Carinii) pneumonia. The present case is significant because of the paucity of similar cases in the literature and the relative frequency with which TMP-SMX is used today.
